Daptomycin: the role of high-dose and combination therapy for Gram-positive infections.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  International Journal of Antimicrobial Agents

• Publication date

  2013-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ijantimicag.2013.05.005PMID 23845504
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Daptomycin use in patients with osteomyelitis: a preliminary report from the EU-CORESM database

  2013cited by this paper
• Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort study.

  2013cited by this paper
• Early In Vitro and In Vivo Development of High-Level Daptomycin Resistance Is Common in Mitis Group Streptococci after Exposure to Daptomycin

  2013cited by this paper
• Activity of linezolid and high-dose daptomycin, alone or in combination, in an in vitro model of Staphylococcus aureus biofilm.

  2012cited by this paper
• Evaluation of the Novel Combination of High-Dose Daptomycin plus Trimethoprim-Sulfamethoxazole against Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus Using an In Vitro Pharmacokinetic/Pharmacodynamic Model of Simulated Endocardial Vegetations

  2012cited by this paper
• Multicenter Evaluation of the Clinical Outcomes of Daptomycin with and without Concomitant β-Lactams in Patients with Staphylococcus aureus Bacteremia and Mild to Moderate Renal Impairment

  2012cited by this paper
• Evaluation of Standard- and High-Dose Daptomycin versus Linezolid against Vancomycin-Resistant Enterococcus Isolates in an In Vitro Pharmacokinetic/Pharmacodynamic Model with Simulated Endocardial Vegetations

  2012cited by this paper
• β-Lactams Increase the Antibacterial Activity of Daptomycin against Clinical Methicillin-Resistant Staphylococcus aureus Strains and Prevent Selection of Daptomycin-Resistant Derivatives

  2012cited by this paper
• Daptomycin Concentrations in Valve Tissue and Vegetation in Patients with Bacterial Endocarditis

  2012cited by this paper
• High-Dose Daptomycin plus Fosfomycin Is Safe and Effective in Treating Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus Endocarditis

  2012cited by this paper
• High-dose daptomycin for cardiac implantable electronic device-related infective endocarditis.

  2012cited by this paper
• Comparative randomised clinical trial against glycopeptides supports the use of daptomycin as first-line treatment of complicated skin and soft-tissue infections.

  2012cited by this paper
• Ceftaroline Increases Membrane Binding and Enhances the Activity of Daptomycin against Daptomycin-Nonsusceptible Vancomycin-Intermediate Staphylococcus aureus in a Pharmacokinetic/Pharmacodynamic Model

  2012cited by this paper
• Fosfomycin-Daptomycin and Other Fosfomycin Combinations as Alternative Therapies in Experimental Foreign-Body Infection by Methicillin-Resistant Staphylococcus aureus

  2012cited by this paper
• Daptomycin-Nonsusceptible Vancomycin-Intermediate Staphylococcus aureus Vertebral Osteomyelitis Cases Complicated by Bacteremia Treated with High-Dose Daptomycin and Trimethoprim-Sulfamethoxazole

  2012cited by this paper
• Daptomycin Pharmacokinetics and Pharmacodynamics in a Pooled Sample of Patients Receiving Thrice-Weekly Hemodialysis

  2012cited by this paper
• In vitro susceptibilities and molecular analysis of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus isolates.

  2012cited by this paper
• Safety analysis of high dose (>6 mg/kg/day) daptomycin in patients with concomitant statin therapy

  2012cited by this paper
• Clinical experience with daptomycin for the treatment of patients with knee and hip periprosthetic joint infections.

  2012cited by this paper
• High-dose daptomycin and fosfomycin treatment of a patient with endocarditis caused by daptomycin-nonsusceptible Staphylococcus aureus: Case report

  2011cited by this paper
• Ampicillin Enhances Daptomycin- and Cationic Host Defense Peptide-Mediated Killing of Ampicillin- and Vancomycin-Resistant Enterococcus faecium

  2011cited by this paper
• Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding.

  2011cited by this paper
• Genetic basis for in vivo daptomycin resistance in enterococci.

  2011cited by this paper
• Daptomycin resistance mechanisms in clinically derived Staphylococcus aureus strains assessed by a combined transcriptomics and proteomics approach.

  2011cited by this paper
• Daptomycin: evaluation of a high-dose treatment strategy.

  2011cited by this paper
• Gentamicin Improves the Activities of Daptomycin and Vancomycin against Enterococcus faecalis In Vitro and in an Experimental Foreign-Body Infection Model

  2011cited by this paper
• Erythromycin and penicillin resistance mechanisms among viridans group streptococci isolated from blood cultures of adult patients with underlying diseases.

  2011cited by this paper
• Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naïve patient—a review of the literature

  2011cited by this paper
• Adjunctive Rifampin Is Crucial to Optimizing Daptomycin Efficacy against Rabbit Prosthetic Joint Infection Due to Methicillin-Resistant Staphylococcus aureus

  2011cited by this paper
• High‐Dose Daptomycin for Treatment of Complicated Gram‐Positive Infections: A Large, Multicenter, Retrospective Study

  2011cited by this paper
• Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary.

  2011cited by this paper
• Skin and soft-tissue infections requiring hospitalization at an academic medical center: opportunities for antimicrobial stewardship.

  2010cited by this paper
• Activities of High-Dose Daptomycin, Vancomycin, and Moxifloxacin Alone or in Combination with Clarithromycin or Rifampin in a Novel In Vitro Model of Staphylococcus aureus Biofilm

  2010cited by this paper
• High-dose daptomycin in documented Staphylococcus aureus infections.

  2010cited by this paper
• High-dose daptomycin for the treatment of endocarditis caused by Staphylococcus aureus with intermediate susceptibility to glycopeptides.

  2010cited by this paper
• Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis.

  2010cited by this paper
• Efficacy of Usual and High Doses of Daptomycin in Combination with Rifampin versus Alternative Therapies in Experimental Foreign-Body Infection by Methicillin-Resistant Staphylococcus aureus

  2010cited by this paper
• Multidrug-Resistant Enterococcus faecium Endocarditis Treated with Combination Tigecycline and High-Dose Daptomycin

  2009cited by this paper
• Relationship between Susceptibility to Daptomycin In Vitro and Activity In Vivo in a Rabbit Model of Aortic Valve Endocarditis

  2009cited by this paper
• Safety and Clinical Outcomes when Utilizing High-Dose (≥8 mg/kg) Daptomycin Therapy

  2009cited by this paper
• Efficacy of Daptomycin in Implant-Associated Infection Due to Methicillin-Resistant Staphylococcus aureus: Importance of Combination with Rifampin

  2009cited by this paper
• Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

  2009cited by this paper
• The Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC)

  2009cited by this paper
• Staphylococcus aureus bacteremia: epidemiology, pathophysiology, and management strategies.

  2009cited by this paper
• Efficacy of High Doses of Daptomycin versus Alternative Therapies against Experimental Foreign-Body Infection by Methicillin-Resistant Staphylococcus aureus

  2009cited by this paper
• Safety and Efficacy of Daptomycin in the Treatment of Osteomyelitis: Results from the CORE® Registry

  2009cited by this paper
• Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program.

  2009cited by this paper
• Effects of daptomycin in combination with other antimicrobial agents: a review of in vitro and animal model studies.

  2009cited by this paper
• Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.

  2008cited by this paper
• Daptomycin: rationale and role in the management of skin and soft tissue infections.

  2008cited by this paper
• Daptomycin Is Effective for Treatment of Experimental Endocarditis Due to Methicillin-Resistant and Glycopeptide-Intermediate Staphylococcus epidermidis

  2008cited by this paper
• Coagulase-negative staphylococcal prosthetic valve endocarditis—a contemporary update based on the International Collaboration on Endocarditis: prospective cohort study

  2008cited by this paper
• A pilot study of high‐dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram‐positive bacteria

  2008cited by this paper
• Activity of Daptomycin Alone and in Combination with Rifampin and Gentamicin against Staphylococcus aureus Assessed by Time-Kill Methodology

  2007cited by this paper
• Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005)

  2007cited by this paper
• Daptomycin Activity against Staphylococcus aureus following Vancomycin Exposure in an In Vitro Pharmacodynamic Model with Simulated Endocardial Vegetations

  2007cited by this paper
• Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies.

  2007cited by this paper
• Biofilm formation by enterococci.

  2007cited by this paper
• Infective endocarditis

  2007cited by this paper
• Evaluation of daptomycin activity against Staphylococcus aureus in an in vitro pharmacodynamic model under normal and simulated impaired renal function.

  2006cited by this paper
• Pharmacokinetics and Tolerability of Daptomycin at Doses up to 12 Milligrams per Kilogram of Body Weight Once Daily in Healthy Volunteers

  2006cited by this paper
• Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.

  2006influential reference
• Staphylococcus aureus endocarditis: a consequence of medical progress.

  2005cited by this paper
• Outpatient parenteral antibiotic therapy (OPAT) in different countries: a comparison.

  2004cited by this paper
• Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci.

  2004cited by this paper
• The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections.

  2004cited by this paper
• Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.

  2004cited by this paper
• Infective endocarditis

  2004cited by this paper
• Osteomyelitis.

  2004cited by this paper
• Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002).

  2004cited by this paper
• Complicated infections of skin and skin structures: when the infection is more than skin deep.

  2004cited by this paper
• Surgical treatment of pacemaker and defibrillator lead endocarditis: the impact of electrode lead extraction on outcome.

  2003cited by this paper
• Daptomycin Dose-Effect Relationship against Resistant Gram-Positive Organisms

  2003cited by this paper
• Changes in the prevalence of vancomycin-resistant enterococci in response to antimicrobial formulary interventions: impact of progressive restrictions on use of vancomycin and third-generation cephalosporins.

  2003cited by this paper
• Daptomycin Pharmacokinetics and Safety following Administration of Escalating Doses Once Daily to Healthy Subjects

  2003cited by this paper
• Pharmacodynamics of Daptomycin in a Murine Thigh Model of Staphylococcus aureus Infection

  2001cited by this paper
• Development of daptomycin for gram-positive infections.

  2000cited by this paper
• Once-Daily Dosing in Dogs Optimizes Daptomycin Safety

  2000cited by this paper
• Daptomycin or teicoplanin in combination with gentamicin for treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faecium

  1992cited by this paper

• Real-World Daptomycin Use with a focus on muscle toxicity: A multicentric retrospective study.

  2026cites this paper
• Endocardite infectieuse

  2025cites this paper
• Efficacy of Ceftobiprole and Daptomycin at Bone Concentrations Against Methicillin-Resistant Staphylococcus aureus Biofilm: Results of a Dynamic In Vitro PK/PD Model

  2025cites this paper
• Derivatization-free CTAB-induced fluorescence sensing strategy for determination of daptomycin in environmental, pharmaceutical, and biological samples

  2024cites this paper
• Getting to the heart of the matter - Are two agents really better than one for the treatment of staphylococcal infective endocarditis?

  2024cites this paper
• 2023 ESC Guidelines for the management of endocarditis.

  2023cites this paper
• Combination drug strategies for biofilm eradication using synthetic and natural agents in KAPE pathogens

  2023cites this paper
• Population Pharmacokinetic Model for Unbound Concentrations of Daptomycin in Patients with MRSA Including Patients Undergoing Hemodialysis

  2023cites this paper
• A critical view on the current use of daptomycin in Spain: The daptomise study.

  2023cites this paper
• Too Much of a Good Thing: Defining Antimicrobial Therapeutic Targets to Minimize Toxicity

  2021cites this paper
• 36/w mit Fieber und Schmerzen im rechten Arm

  2021cites this paper
• The choice of antimicrobial therapy for infective endocarditis in the conditions of gram-positive microorganism dominance in the etiological structure in the russian federation

  2021cites this paper
• Daptomycin versus teicoplanin in the treatment of osteomyelitis: Results of the Göztepe retrospective cohort study.

  2021cites this paper
• The Efficacy and Safety of High-dose Daptomycin in the Treatment of Complicated Skin and Soft Tissue Infections in Asians.

  2020cites this paper
• Comparing probability of target attainment against Staphylococcus aureus for ceftaroline fosamil, vancomycin, daptomycin, linezolid, and ceftriaxone in complicated skin and soft tissue infection using pharmacokinetic/pharmacodynamic models.

  2020cites this paper
• Glycopeptides et lipopeptides

  2020cites this paper
• Efficacy and Safety of High Vs Standard Daptomycin Doses Examined in Chinese Patients With Severe Burn Injuries by Pharmacokinetic Evaluation

  2020cites this paper
• Impact of Daptomycin Dose Exposure Alone or in Combination with β-Lactams or Rifampin against Vancomycin-Resistant Enterococci in an In Vitro Biofilm Model

  2020cites this paper
• First case of Abiotophia defectiva infectious endocarditis treated with a combination of amoxicillin and daptomycin

  2020cites this paper
• Development and validation of sensitive and selective quantification of total and free daptomycin in human plasma using ultra‐performance liquid chromatography coupled to tandem mass spectrometry

  2019cites this paper
• Antimicrobial Desensitization: A Review of Published Protocols

  2019cites this paper
• Daptomycin-containing regimens for treatment of gram-positive endocarditis.

  2019cites this paper
• Multifunctional Pharmaceutical Effects of the Antibiotic Daptomycin

  2019cites this paper
• Synthetic ionophores as non-resistant antibiotic adjuvants

  2019cites this paper
• Pharmacodynamic comparison of different antimicrobial regimens against Staphylococcus aureus bloodstream infections with elevated vancomycin minimum inhibitory concentration

  2019cites this paper
• Time-kill curves of daptomycin and Monte Carlo simulation for the treatment of bacteraemia caused by Enterococcus faecium

  2019cites this paper
• Current use of daptomycin and systematic therapeutic drug monitoring: Clinical experience in a tertiary care institution.

  2019cites this paper
• Hip and Knee Section, Treatment, Antimicrobials: Proceedings of International Consensus on Orthopedic Infections.

  2019cites this paper
• Impact of beta-lactam and daptomycin combination therapy on clinical outcomes in methicillin-susceptible Staphylococcus aureus bacteremia: A propensity score-matched analysis.

  2019cites this paper
• Daptomycin Plus Fosfomycin as Salvage Therapy in a Difficult-to-Treat Total Femoral Replacement Infection

  2018cites this paper
• Gram-positive Bacterial Infections

  2018cites this paper
• Safety of high-dose daptomycin in patients with severe renal impairment

  2018cites this paper
• Anti-infective therapy in special patient populations based on therapeutic drug monitoring

  2018cites this paper
• Treatment of severe MRSA infections: current practice and further development

  2017cites this paper
• The Use of Daptomycin to Treat Methicillin-Resistant Staphylococcus Epidermidis Bacteremia in a Critically Ill Child with Renal Failure.

  2017cites this paper
• Practice Point 39 – Management Strategies for Drug-Resistant Infections

  2017cites this paper
• Role of rifampin for the treatment of bacterial infections other than mycobacteriosis.

  2017cites this paper
• Antimicrobial Peptide Daptomycin and its Inhibition by Pulmonary Surfactant: Biophysical Studies using Model Membrane Systems

  2017cites this paper
• Pharmacokinetic/pharmacodynamic parameters for treatment optimization of infection due to antibiotic resistant bacteria: a summary for practical purposes in children and adults

  2017cites this paper
• Successful management of a complicated clinical crisis

  2017cites this paper
• Intraosteoblastic activity of daptomycin in combination with oxacillin and ceftaroline against MSSA and MRSA

  2017cites this paper
• Recently approved antibacterials for methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive pathogens: the shock of the new.

  2017cites this paper
• Pharmacotherapeutic options for treating Staphylococcus aureus bacteremia

  2017cites this paper
• Fitness Cost of Daptomycin-Resistant Staphylococcus aureus Obtained from in Vitro Daptomycin Selection Pressure

  2017influential citation
• SASCM guideline for daptomycin use in South Africa – 2017 update

  2017cites this paper
• Gram-Positive Bacterial Infections After Haematopoietic Stem Cell or Solid Organ Transplantation

  2016cites this paper
• Hot topics in the diagnosis and management of skin and soft-tissue infections.

  2016cites this paper
• Daptomycin: an evidence-based review of its role in the treatment of Gram-positive infections

  2016cites this paper
• Rifampicin-containing combinations are superior to combinations of vancomycin, linezolid and daptomycin against Staphylococcus aureus biofilm infection in vivo and in vitro.

  2016cites this paper
• Towards a definition of daptomycin optimal dose: Lessons learned from experimental and clinical data.

  2016cites this paper
• Methicillin-resistant Staphylococcus aureus infections: A review of the currently available treatment options.

  2016cites this paper
• Safety of treatment with high-dose daptomycin in 102 patients with infective endocarditis.

  2016cites this paper
• [Advances in the study of anti-MRSA natural products].

  2016cites this paper
• Guía ESC 2015 sobre el tratamiento de la endocarditis infecciosa

  2016cites this paper
• Pharmacodynamic Considerations in Critically Ill Patients

  2016cites this paper
• Enfermedades Infecciosas y Microbiología Clínica

  2016cites this paper
• Daptomycin in paediatrics: current knowledge and the need for future research.

  2015cites this paper
• Analysis of 5-year trends in daptomycin activity tested against Staphylococcus aureus and enterococci from European and US hospitals (2009-2013).

  2015cites this paper
• Daptomycin in the Clinical Setting: 8-Year Experience with Gram-positive Bacterial Infections from the EU-CORESM Registry

  2015cites this paper
• Daptomycin for the treatment of osteomyelitis and orthopaedic device infections: real-world clinical experience from a European registry

  2015cites this paper
• Antimicrobial Stewardship Intervention and Feedback to Infectious Disease Specialists: A Case Study in High-Dose Daptomycin

  2015cites this paper
• Methicillin-resistant Staphylococcus aureus infections : role of daptomycin / β-lactams combination infezioni da staphylococcus aureus meticillino-resistente : ruolo

  2015cites this paper
• Evaluation of Effectiveness and Safety of High-Dose Daptomycin: Results from Patients Included in the European Cubicin® Outcomes Registry and Experience

  2015cites this paper
• 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM).

  2015cites this paper
• Clinical pharmacological approach for balancing the use of daptomycin and linezolid in comparison with that of vancomycin in the treatment of MRSA-related infections

  2015cites this paper
• Clinical experience with the use of daptomycin in a tertiary care teaching hospital in Barcelona, Spain.

  2015cites this paper
• Daptomycin: Physicochemical, Analytical, and Pharmacological Properties

  2015cites this paper
• Heterogeneity of Genetic Pathways toward Daptomycin Nonsusceptibility in Staphylococcus aureus Determined by Adjunctive Antibiotics

  2015cites this paper
• Infektiöse Endokarditis – Epidemiologie, Diagnostik und Therapie

  2015cites this paper
• Therapeutic cyclic lipopeptides mining from microbes: latest strides and hurdles

  2015cites this paper
• Infektiöse Endokarditis - Epidemiologie, Diagnostik und Therapie DFP-Fortbildung

  2015cites this paper
• Treatment of Methicillin-Resistant Staphylococcus aureus: Vancomycin and Beyond

  2015cites this paper
• Therapeutic Drug Monitoring of Daptomycin: A Retrospective Monocentric Analysis

  2015cites this paper
• Pharmacokinetic and pharmacodynamic considerations of antimicrobial drug therapy in cancer patients with kidney dysfunction.

  2015cites this paper
• [2015 ESC Guidelines for the management of infective endocarditis].

  2015cites this paper
• In Vitro Activity of Daptomycin in Combination with β-Lactams, Gentamicin, Rifampin, and Tigecycline against Daptomycin-Nonsusceptible Enterococci

  2015cites this paper
• Use of Selected Antibiotics in the Elderly

  2015cites this paper
• Does vancomycin have a future in the treatment of skin infections?

  2014cites this paper
• [Potential utility of ceftaroline fosamil in osteoarticular infections].

  2014cites this paper
• Daptomycin activity tested against 164457 bacterial isolates from hospitalised patients: summary of 8 years of a Worldwide Surveillance Programme (2005-2012).

  2014cites this paper
• Mechanisms of infective endocarditis: pathogen–host interaction and risk states

  2014cites this paper
• High doses of daptomycin (10 mg/kg/d) plus rifampin for the treatment of staphylococcal prosthetic joint infection managed with implant retention: a comparative study.

  2014cites this paper
• Infusion-Related Reaction following Daptomycin Two-Minute Rapid Intravenous Administration

  2014cites this paper
• Pharmacological Agents for the Treatment of Skin and Soft Tissue Infections: What is the Role for Daptomycin?

  2014cites this paper
• Oritavancin Activity against Staphylococcus aureus Causing Invasive Infections in U.S. and European Hospitals: a 5-Year International Surveillance Program

  2014cites this paper
• Therapieoptionen bei Infektion durch nosokomiale multiresistente Erreger

  2014cites this paper
• Daptomycin in combination with other antibiotics for the treatment of complicated methicillin-resistant Staphylococcus aureus bacteremia.

  2014cites this paper
• Rapid emergence of daptomycin resistance in clinical isolates of Corynebacterium striatum… a cautionary tale

  2014cites this paper
• Activity of Daptomycin or Linezolid in Combination with Rifampin or Gentamicin against Biofilm-Forming Enterococcus faecalis or E. faecium in an In Vitro Pharmacodynamic Model Using Simulated Endocardial Vegetations and an In Vivo Survival Assay Using Galleria mellonella Larvae

  2014cites this paper
• Treatment options for methicillin-resistant Staphylococcus aureus (MRSA) infection: Where are we now?

  2014cites this paper
• What's new in the treatment of serious MRSA infection?

  2014cites this paper
• Relationship between consumption of MRSA-active antibiotics and burden of MRSA in acute care hospitals in Catalonia, Spain.

  2014cites this paper